Möchten Sie immer auf dem neuesten Stand bleiben?

THE WOODLANDS, Texas, March 11, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that results of a post hoc analysis of clinical data evaluating the impact of...

GLP Diet is a personalized weight loss app supporting GLP-1 meds with tailored meals, workouts, trackers, and expert guidance for fast and lasting results.

Austin, TX, USA, March 10, 2026 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Intravenous Infusion Pump Market Size, Trends and Insights By Product Type...

MANNKIND TO PRESENT NEW DATA FROM PEDIATRIC AND ADULT STUDIES OF AFREZZA® AT ATTD 2026

Austin, TX, USA, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Hydrogel Wound Dressing Market Size, Trends and Insights By Product Type...

Arlington, VA, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Inspire, the world’s largest free online community and support group for patients and caregivers, today announced the launch of two new dedicated...

NEW YORK, Feb. 17, 2026 (GLOBE NEWSWIRE) -- The Juvenile Diabetes Cure Alliance (JDCA), a 501(c)(3) nonprofit focused on accelerating a cure for type 1 diabetes (T1D), announced the release of a...

TORONTO, Feb. 09, 2026 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) today announced that a scientific team led by Dr. Justin Chun at the...

MannKind Announces First Patient Enrolled in INHALE-1ST Pediatric Study Evaluating Afrezza® for Youth with Newly-Diagnosed Type 1 Diabetes (T1D)

Prof. Carl D. Regillo, MD, presented clinical data from the Phase 1b trial evaluating Breye Therapeutics’ lead candidate, danegaptide, in 24 patients with non-proliferative diabetic retinopathy (NPDR)...